App-Quantinova.ai

Polymyositis/Dermatomyositis Readmissions: Analysis of the Nationwide Readmission Database

Amy Trang - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Polymyositis and dermatomyositis

N/A

Poor Serum Urate Control Is a Driver of Excess Cardiovascular Risk in Patients with Gout

Tate Johnson - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Gout

N/A

Population Based Prevalence and Incidence of Mixed Connective Tissue Disease from the Manhattan Lupus Surveillance Program

Ghadeer Hasan - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Raynaud syndrome

N/A

Post-operative Delirium and Cognitive Impairment: An Analysis of Predictors and 120-day Outcomes in England Using the National Hip Fracture Database (NHFD)

Andrew Judge - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Postoperative delirium

N/A

Predicting Progression from Undifferentiated to Definitive Connective Tissue Diseases: A Systematic Review and Meta-analysis

Sarah Dyball - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Predictive Factors of Eosinophilic Granulomatosis with Polyangiitis Long-term Evolution: Data from a European Cohort

Matthias Papo - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Eosinophilic granulomatosis with polyangiitis

Glucocorticoid

Predictors of Fragility Fracture Amongst Patients with Rheumatoid Arthritis: An Observational Cohort Study

Seema Sharma - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Predictors of Nail Response with Guselkumab: A Post Hoc Analysis of the VOYAGE 2 Clinical Trial

Alexander Egeberg - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

Adalimumab

Prevalence of Secondary Connective Tissue Diseases and Autoantibodies Among Racial and Ethnic Groups in Systemic Lupus Erythematosus Patients in the Manhattan Lupus Surveillance Program

Brendan Denvir - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Lupus

N/A

Prevalence, Risk Factors and Treatment Patterns of Digital Ischemic Complications in Systemic Sclerosis: A Single Center Cross-Sectional Study

Ashima Makol - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Aspirin

Primary Non-adherence to Biologics and Immunomodulatory Therapies for Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis Using Linked EHR and Pharmacy Claims Data

Jeffrey Curtis - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Axial spondyloarthritis

N/A

Probability-based Diagnostic Algorithm in Suspected Giant Cell Arteritis: A Prospective, Multicentre Validity Data from HAS GCA Study

Alwin Sebastian - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Giant cell arteritis

Glucocorticoid

Prognosis of Non-PR3 ANCA-Associated Vasculitis with Glomerulonephritis

Aurélien Chepy - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anti-neutrophil cytoplasmic antibody-associated vasculitis

Mycophenolate mofetil

Pulmonary Manifestations in VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome: A Systematic Literature Review

Koushan Kouranloo - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Race and Disease Severity Predict Reduced Response to Treat-to-Target Urate Lowering Therapy in Gout: Post-hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial

Lindsay Helget - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Gout

Allopurinol

Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers

Lucy Marie Carter - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Cutaneous lupus erythematosus

MDX1333

Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis in Europe

Ran Jin - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Adalimumab biosimilar

Recovery of Renal Function Among ANCA-Associated Vasculitis Patients with Baseline eGFR ≤20 in the Avacopan ADVOCATE Trial

David Jayne - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Anti-neutrophil cytoplasmic antibody-associated vasculitis

CCX-168

Recurrent Thrombosis Risk in Non-anticoagulated Antiphospholipid Syndrome Patients: A Prospective Case-Control Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

Cecile Yelnik - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

N/A

Reduction in Structural Damage Progression and Improvement in Clinical Response with Abatacept Treatment in Patients with ACPA+, Early RA: Results from a Post Hoc Analysis of the AVERT-2 Study by Baseline Erosion Scores

Chahin Pachai - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Abatacept

Filters

45280 Abstracts